Elanco Animal Health Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Elanco Animal Health Inc. operates as a single global segment focused on animal health products for pets and farm animals. The company is a large accelerated filer with approximately 499.4 million shares of common stock outstanding as of May 1, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $1,371 million | $1,193 million |
| Gross Profit | $785 million | $684 million |
| Gross Margin | 57.3% | 57.3% |
| Net Income | $57 million | $67 million |
| Diluted EPS | $0.11 | $0.13 |
| Operating Cash Flow | $13 million | ($4 million) |
| Cash and Equivalents | $428 million | $487 million |
| Total Debt (Long-term + Current) | $3,991 million | $4,017 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year, driven by volume growth in both Pet Health (+12%) and Farm Animal (+18%) segments, alongside favorable pricing and foreign currency impacts.
- Profitability Decline: Despite revenue growth, Net Income decreased 15% to $57 million. This was primarily due to a $17 million increase in interest expense (largely driven by $14 million in imputed interest on a liability for sale of future revenue) and a $7 million increase in restructuring charges.
- Restructuring Charges: Asset impairment, restructuring, and other special charges rose to $16 million from $9 million, primarily due to $15 million in non-cash shut-down costs for R&D facilities in Monheim, Germany.
- Effective Tax Rate: The effective tax rate was 34.6% in Q1 2026, compared to a tax benefit (negative rate) of (12.2)% in Q1 2025, reflecting a shift from utilizing net operating losses to recognizing global minimum taxes.
Guidance, Outlook, and Risks
- Acquisition: On April 30, 2026, Elanco completed the acquisition of AHV International B.V. for an initial $76 million, with up to $240 million in additional contingent payments. AHV is expected to contribute modestly to 2026 revenue with a more meaningful impact in 2027.
- Product Pipeline: Key launches include Zenrelia (approved Sept 2024) and Credelio Quattro (launched Jan 2025). Befrena, a new monoclonal antibody for canine dermatitis, is anticipated to launch in Q2 2026.
- Restructuring Outlook: The 2025 Restructuring Plan targets $25 million to $30 million in pre-tax charges for 2026, with expected annual savings of $25 million in 2026 and $60 million in 2027.
- Trade and Regulatory Risks: New U.S. tariffs on pharmaceuticals were announced in April 2026 but are not effective until Q3 2026; animal health products currently have significant carve-outs. The company notes uncertainty regarding the adoption of sustainability products like Bovaer due to the freezing of certain government incentives.
- Liquidity: The company maintains $428 million in cash and approximately $750 million in unused capacity on its Revolving Credit Facility. It remains in compliance with all debt covenants.
Investor Verification Checklist
- Imputed Interest Impact: Verify the sustainability of the $14 million quarterly imputed interest expense related to the sale of future royalty rights to Blackstone and its long-term effect on net income.
- Restructuring Execution: Monitor the realization of the projected $25 million in 2026 savings from the 2025 Restructuring Plan against the remaining $11 million to $16 million in expected charges.
- Regulatory Tariffs: Confirm the final scope of Q3 2026 tariffs on pharmaceuticals to ensure animal health products remain exempt from new U.S. trade policies.
- Legal Proceedings: Track the status of the pending appeal in the Barpar securities class action and the settlement discussions regarding the Kraus-Silfen and Spradlin matters.
- Foreign Currency Exposure: Assess the impact of continued foreign currency fluctuations, which contributed significantly to Q1 2026 revenue growth but also increased expenses.